Table 2. Effects of tetrandrine treatment in combination with other agents on cancer cells.
| Name of agent | Cancer cell line | Therapeutic effects | References |
|---|---|---|---|
| 5-FU | HCT116 | β-catenin – Migration and Invasion | [39] |
| Imatinib | K562, primary leukemia cells | G1 arrest, Depletion of p210 (Bcr-Abl) mRNA and β-catenin protein | [92] |
| Endostar | LoVo, human colon cancer | Apoptosis, Cell cycle arrest, Angiogenesis, Metastasis | [102] |
| Docetaxel | KBv200 | Inhibition of P-gp, Apoptosis | [85] |
| Vincristine | KBv200 | Binding to P-gp- reversed resistance | [86] |
| Doxorubicin | Caco-2, CEM/ADR5000, MOLT-4/DNR, K562 | Reducing P-gp expression, inhibition of mmdr1, mRNA/P-gp and NF-kappaB | [87, 88, 91] |
| Daunorubicin | MOLT-4/DNR, K562/A02 | Down-regulating GCS- Apoptosis | [88, 90] |
| Vinblastine | MOLT-4/DNR | Inhibition of P-gp | [88] |
| Daunorubicin, Etoposide and Cytarabine | acute myeloid leukemia | More tolerated in clinical trial for patients | [89] |
| Cisplatin | YES-2/DDP, ovarian cancer, | Wnt/cadherin-apoptosis, Down-regulation of MRP1 | [94, 95] |
| * Sorafenib | BEL7402, FHCC98, HepG2, HCT116, RKO, DLD1 | ROS/Akt, Apoptosis | [52] |
| Arsenic trioxide | HepG2, A549 | Apoptosis, necrosis and cell cycle arrest | [100] |
| * Chloroquine | Huh7, FHCC98, U87, U251, Calu-1, A549, HeLa | ROS/p21CIP1/WAF1- Apoptosis | [75] |
| PTX and PTX loaded nanoparticles | KBv200, gastric cancer | ROS, Apoptosis | [85] |
| Lactoferrin-conjugated polymer, some holding doxorubicin (Lf-PO-Dox) | C6 glioma cells | Inhibition of tumor growth | [93] |
*
Studies involving our laboratory